- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07592416
Clinical, Microbiological and Immunological Effects of the Adjuvant Use of Systemic Antibiotics and Probiotics in the Non-surgical Treatment of Periodontitis
Clinical, Microbiological and Immunological Effects of the Adjuvant Use of Systemic Antibiotics and Probiotics in the Non-surgical Treatment of Periodontitis: a Controlled and Randomized Clinical Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Scaling and root planing (SRP) is the most widely used treatment modality in periodontal therapy. However, a subset of periodontal sites does not respond adequately to this approach, and certain individuals exhibit susceptibility patterns that limit their response to initial treatment. Therefore, to overcome the limitations of SRP alone, adjunctive therapies-such as antibiotics and probiotics-may be employed.
The aim of this randomized, controlled, double-blind clinical trial is to evaluate the effects of adjunctive therapies (antibiotics and probiotics) associated with non-surgical periodontal therapy in individuals diagnosed with periodontitis stages III or IV, grades B or C. A total of sixty individuals with a clinical diagnosis of periodontitis will be treated with SRP alone or SRP combined with antibiotics or probiotics. Participants will be randomly allocated into three groups: Control (SRP), Test 1 (SRP + amoxicillin and metronidazole), and Test 2 (SRP + probiotics).
The adjunctive agents evaluated in this study will be a combination of systemic antibiotics (amoxicillin and metronidazole) and the probiotic Bifidobacterium animalis subsp. lactis HN019. Antibiotics will be administered for 14 days, three times daily, whereas probiotics will be administered for 90 days, twice daily. Adjunctive therapies will commence immediately after the first week of periodontal instrumentation.
Clinical follow-up will be conducted at baseline (pre-intervention), and at 3, 6, 9, and 12 months post-treatment. At baseline, 6 months, and 12 months, gingival crevicular fluid, subgingival biofilm, peripheral blood, and fecal samples will be collected, along with the assessment of periodontal clinical parameters. Levels of the cytokines IL-6, TNF-α, IFN-γ, IL-10, IL-1β, and IL-8 will be quantified in gingival crevicular fluid and peripheral blood samples using enzyme-linked immunosorbent assays.
Subgingival biofilm and fecal samples will be subjected to 16S ribosomal RNA gene amplification by PCR and sequenced using Illumina technology (MiSeq or MiniSeq; Illumina, San Diego, CA, USA). Sequencing data will be analyzed using reference databases of the human oral and intestinal microbiomes. Statistical analyses will be performed using an alpha level of 0.05 (p < 0.05).
Type d'étude
Inscription (Réel)
Phase
- Première phase 1
Contacts et emplacements
Lieux d'étude
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brésil, 14040-904
- Universidade de São Paulo
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults with a diagnosis of generalized periodontitis, defined as involvement of ≥30% of teeth, classified as: Stage III or Stage IV, and Grade B or Grade C, according to the 2018 classification.
- Presence of at least one tooth with ≥1 interproximal site exhibiting: Probing depth (PD) ≥6 mm, and Clinical attachment loss (CAL) ≥5 mm.
- Presence of at least 15 teeth, excluding third molars and teeth indicated for extraction.
- Presence of at least 6 non contiguous teeth, each with ≥1 interproximal site presenting PD and CAL ≥5 mm.
Exclusion Criteria:
- Current smokers or former smokers who quit less than 5 years prior to enrollment.
- Pregnant or breastfeeding women.
- History of periodontal treatment within the previous 6 months.
- Continuous use of oral antiseptics within the last 6 months.
- Use of systemic antibiotics, corticosteroids, non steroidal anti inflammatory drugs, immunosuppressants, estrogen, estrogen receptor modulators, or medications affecting bone metabolism (e.g., alendronate, calcitonin) within the last 6 months.
- Presence of systemic conditions that may alter the host response, including: Diabetes mellitus, HIV infection, Down syndrome.
- Medical conditions requiring antibiotic prophylaxis for dental procedures (e.g., mitral valve prolapse).
- Known allergy or hypersensitivity to amoxicillin, metronidazole, penicillins, or related compounds.
- Use of probiotics within the last 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Placebo
|
|
|
Expérimental: Probiotic
To compare the effects of probiotic as an adjuvant therapy
|
Patients will receive probiotic lozenges as an adjuvant therapy to periodontal treatment.
|
|
Expérimental: Antibiotic
To compare the effects as an adjuvant therapy
|
The antibiotic group will receive amoxicilin and metronidazole, the probiotic group will receive probiotics
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Periodontal Probing Depth (PD)
Délai: every 3 months, up to 1 year
|
A full-mouth periodontal examination will be performed using a North Carolina periodontal probe (Hu-Friedy, Chicago, IL, USA).
Probing depth (PD) will be measured in millimeters at six sites per tooth.
|
every 3 months, up to 1 year
|
|
Clinical Attachment Level (CAL)
Délai: Every 3 months, up to 1 year
|
Clinical attachment level (CAL) will be measured in millimeters at six sites per tooth using a North Carolina periodontal probe.
|
Every 3 months, up to 1 year
|
|
Bleeding on Probing (BOP)
Délai: Every 3 months, up to 1 year
|
Bleeding on probing will be assessed dichotomously (presence/absence) at six sites per tooth during full-mouth periodontal examination
|
Every 3 months, up to 1 year
|
|
Visible Supragingival Biofilm
Délai: Every 3 months, up to 1 year
|
Presence or absence of visible supragingival biofilm will be assessed on four tooth surfaces during full-mouth periodontal examination.
|
Every 3 months, up to 1 year
|
|
Distance from Cementoenamel Junction to Gingival Margin
Délai: Every 3 months, up to 1 year
|
The distance from the cementoenamel junction to the gingival margin will be measured in millimeters at six sites per tooth.
|
Every 3 months, up to 1 year
|
|
Suppuration
Délai: Every 3 months, up to 1 year
|
Suppuration will be assessed dichotomously (presence/absence) at six sites per tooth during periodontal examination.
|
Every 3 months, up to 1 year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Michel Reis Messora, PhD, University of Sao Paulo
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies de la bouche
- Maladies stomatognathiques
- Parodontite
- Maladies parodontales
- Agents anti-infectieux
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Azoles
- Actions pharmacologiques
- Actions et utilisations chimiques
- Utilisations thérapeutiques
- Imidazoles
- Nitroimidazoles
- Composés nitro
- Métronidazole
- Agents antibactériens
Autres numéros d'identification d'étude
- 75898223.7.0000.5419
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .